CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer

Zhenguo Cheng; Danhua Zhang; Baocheng Gong; Pengliang Wang; Funan Liu

doi:10.18632/oncotarget.20244

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer

Zhenguo Cheng, Danhua Zhang, Baocheng Gong, Pengliang Wang and Funan Liu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:87244-87262. https://doi.org/10.18632/oncotarget.20244

Metrics: PDF 2611 views | HTML 4905 views | ?

Abstract

Zhenguo Cheng1, Danhua Zhang3, Baocheng Gong2, Pengliang Wang2 and Funan Liu2

1National Center for The International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China

2Department of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China

3Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Correspondence to:

Funan Liu, email: [email protected]

Zhenguo Cheng, email: [email protected]

Keywords: CD163, gastric cancer, prognosis, STAT3, macrophages

Received: January 10, 2017 Accepted: July 18, 2017 Published: August 14, 2017

ABSTRACT

CD163 is a member of the scavenger receptor cysteine-rich superfamily, and has been widely used to identify M2 type macrophage. However, the expression of CD163 in gastric cancer and its regulatory mechanism are still unclear. Here we show that CD163 is elevated in gastric cancer tissues. High expression of CD163 is a potential indicator to evaluate the status of tumor associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and cancer associated fibroblasts (Cafs). Besides, more CD163 positive macrophages and CD163 expressing gastric cancer cells are associated with tumor invasion and poor prognosis. Knocking-down CD163 in cancer cells could inhibit tumor growth in vivo. We also find various immune molecules which are correlated with CD163 in gastric cancer tissues and cell lines have positive staining in the cancer cells of clinical sample. Finally, we confirm CD163 is a novel target gene of STAT3 (signal transducer and activator of transcription 3) in gastric cancer. Our data indicate that CD163 may be a potential poor prognostic marker and therapeutic target for gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20244

Publication Alerts

Research Papers:

CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer

Abstract